Go or no go? The FDA plays hardball
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
New Nuplazid use in limbo after US knockback
Acadia becomes the latest to fall foul of the US FDA's apparently increasingly strict stance.
Biogen’s Sage advice amounts to $1.5bn
Sage gets a big endorsement for zuranolone, but the markets say it should have waited until it had a stronger negotiating position.
Finding the next Vertex
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
Neurocrine picks Takeda’s brain
Neurocrine Biosciences' latest collaboration, with Takeda, gives it three more high-risk bets in neuroscience.
Rett failure sets up thin pipeline
Newron’s failure in Rett syndrome leaves the late-stage pipeline to GW Pharma, Acadia and Anavex.
First fragile X test is approved, and Zynerba could benefit
The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.
